Would you rather have purchases of current labs (obv costing more and possible dilution but instant revenues) or new leases requiring build out and calibration but hopefully less start up cost and less/no dilution possibly slower revenues without customer base (or do you think demand will be so high all labs will be busy at first and it comes down to systematics and efficiency)?

I think at first it was worth the goodwill of customer base and staff but now we should be able to have new leases be best.

Well buying when I can but deff like where we are going and believe in the story.

Same!

Agree. Happy I was able to accumulate for past two years and where this is headed, although not as fast as we dream it would be, but headed in the right direction and about to gain traction.

The negative- dilution into Q1. The positive- revenues and brand awareness should be catching up by then. I personally would like PR with revenue updates at months end (and am hopeful for it as was done when SGBY had record breaking revenues when Oregon first implemented mandated testing).

2018*

These are the expansion types I want to see. They are at the breakthrough point now. New labs take some time to set up and to get certified but they now have ample locations to be able to train and expand more rapidly. The more locations the easier expansion. They should also be able to get bulk equipment or a deal with lab equipment companies to help with build outs. Also if the demand is that high then buying goodwill and a customer base isn’t as important. Hopefully we can be ready by Q1 Oct 2019 for reporting Feb but this lab will be cutting it close and most likely won’t make a full Q1 revenues. I’d be super happy with a deal like this in Canada as well.

IMO, another year or so until we break through the revenues. And then we’ll be ready to expand into the newer markets opening in North East and medicinal states by the time the laws are implemented. The last two years have been alittle long but I think starting the February the next two will be a lot of growth. This is a good time to accumulate.

I do want to make some time this week to look at all our labs and look into Mass law.

I have E*TRADE I’ll pay attention next time.

Good article. Thanks.

Thanks

Did anyone notice the t trade count yesterday?

Been here for over 2 years with about 55k shares.

No we understand market share is important but the dilution is crippling. He’s doing what he needs to do for the business. EVIO is posed to be successful. But there is a lack of investors in penny land especially when the company is diluting and in a federal illegal market. You’re new to this investment so you have more patience to give than those who expected a return when there was 3 labs and now 500% more but share price is in half. We have a different perspective to the situation. You’re not necessarily wrong to see EVIOs potential and WW and Loris work but it’s frustrating when you put us down like we don’t know what we are talking about and haven’t been patient. Most of us are still believers but we want revenues to catch up to dilution but it seems we are still far away from that. Which is why Tar includes the debentures into his projections because by the time the estimate revenues are documented those convertibles will be converted.

I’ve been wanting to tell him how annoyed I get when he says just give it a year, nothing is over night, and stop being a baby type remarks. You hit it on the head. We’ve been here for two years or more with significant business growth without share price growth. Although we do understand it was the only option and market share is important, dilution is crippling us. We need revenues to catch up and I don’t see that until February Q1. This is still “penny land” and not enough people invest in these to support the dilution. I still believe we are on the right track but our market cap is getting higher with no increase in share price and that is the biggest problem. I don’t see any upside until Q1 filings.

So what is your share price estimate valuation at $10million revs, which is projected for fiscal year 2019? What are the p/e of Canadian Cannabis companies.

We need a share price of $4, market cap of $45m, and earnings of $11m one year and two prior years $2.2m without a net loss. There’s other ways though.

https://www.investopedia.com/ask/answers/nasdaq-listing-requirements/

That’s about 2.5 years away. IMO. We have a Canadian listing and an OTCQX up list next.

What’s Tar value at $10 million revenues, which is 2019 estimate? We have a market cap of about $20 million currently.

I have been here since SGBY, as many of us have. We didn’t expect the testing to take so long to go into effect. Oregon had issues of over supply from too many cultivators which is IMO why revenues were low. We spent a lot of dilution on labs that won’t show revenue until Q1 (because of laws). I understand we needed to mark our territory and it’s our fault for buying too early essentially. But I know not to follow this until the K at minimum or Q1 in February really. I’m loaded up on all the shares so I wait. But it’s a good time for others to accumulate slowly as they catch on to the brand. As we open in more states and testing is mandated well eventually have more followers. But as Tar has said forever, revenues must keep up with dilution for evaluation.

We will know mid February for Q1. And hope all our Cali labs are up and running. We waiting awhile last year for a calibration. But you are correct. Fighting dilution and not revealing reflecting revs until mid February call for rockiness. Show me the money (revenues and margins)!

EVIO Inc. Enters into Binding Agreement with MRX Labs to Expand Market Share Dominance in Oregon
EVIO Logo (PRNewsfoto/EVIO, Inc.)
NEWS PROVIDED BY
EVIO Inc.
08:00 ET
MRX Xtractors and EVIO Labs Team Up to Form Strategic Alliance

BEND, Ore., June 28, 2018 /PRNewswire/ -- EVIO Inc. ("EVIO" or the "Company"), (OTCQB: EVIO), a leading provider of cannabis testing and scientific research for the regulated cannabis industry in North America, is pleased to announce that it has entered into an asset purchase agreement with MRX Labs, LLC, an Oregon-based, award-winning testing lab. The Company has also formed a strategic alliance with MRX Xtractors, leveraging the two leading companies' respective strengths, to develop and expand growth in existing and new markets.

MRX Labs, LLC has a state-of-the-art testing facility and is highly respected for its excellent customer service and efficiency. As part of the acquisition, EVIO Labs Portland will relocate to the former MRX Labs location, and the new lab will operate as EVIO Labs Portland. This move will provide EVIO additional operational capacity, as well as an extensive book of business that extends across the state.

"We are excited about the opportunity to further expand our reach and solidify our position as the dominant testing lab in Oregon," said William Waldrop, CEO of EVIO. "As the Oregon market matures, there is a consolidation of the marketplace occurring, and this alliance is a win-win for both of our companies and our customers."

MRX Labs, LLC and MRX Xtractors, founded by Paul Tomaso, CEO and CTO, and Jonah Barber, President, have been research and development, design and engineering pioneers in both analytical testing and extraction technologies. "This relationship with EVIO affords MRX Xtractors an opportunity for us to focus on the global expansion of our extraction technologies, and to unite our testing lab with a company of scientists and professionals whom we trust will take great care of our loyal lab customers and employees," said Barber. "We are thrilled with our newly formed alliance that give us great confidence to refer our extraction customers, across the US and Canada, to EVIO's network of labs and vice-versa."

Transaction Details
Pursuant to the Agreement, EVIO Inc. will purchase 100% of the assets of MRX Labs, LLC including equipment, real estate, customer lists, customer contracts, rental agreements, and equipment leases. EVIO Labs Portland will relocate its personnel and license to the Tigard facility. The transaction is expected to close on or before July 11, 2018.

About EVIO Inc.
EVIO Inc. is a leading provider of cannabis testing and scientific research for the regulated cannabis industry. The Company's EVIO Labs division operates coast-to-coast providing state-mandated ancillary services to ensure the safety and quality of the nation's cannabis supply. The Company's EVIO Biosciences Division is dedicated to the scientific, medical, and psychosocial exploration of clinical cannabis, cannabinoids, and the endocannabinoid system.
For more information, visit www.eviolabs.com.

About MRX Labs
MRX Labs, LLC is a premier cannabis and hemp services company based in Tigard, Oregon. MRX Labs offers full-spectrum bio-analytical services for all testing needs. Our highly trained professionals and cutting-edge testing procedures have set the standard for precision and quality. MRX Labs was named "The Best Testing Facility in Oregon" in 2016 and 2017 by Dope Magazine.
For more information, visit www.mrxlabs.com.

About MRX Xtractors
Based in Canby, Oregon, MRX Xtractors is the market leader in commercial Co2 and ethanol extraction systems for the cannabis and hemp industries. The MRX leadership has an extensive analytical testing background which continues to drive their innovation and design. With a growing list of award-winning customers, MRX has become the most respected manufacturer of extraction technologies.
For more information, visit www.mrxxtractors.com.

Same

The only flipper flipping here that wouldn’t be losing is the dilutors. Any other flipper flipping here is flipping for a loss. The flippers may be the support buying here.

Over 200k volume again. People see potential. We are being driven down by dilution.

Lots of volume in the sub $1.10. I added a small amount here. I still plan to hold long. At least another year or two. Everything is a mystery gamble until we see Q1 revs next February. My groundhogs shadow says 6 more months of rockiness until we see the K to see what Cali testing laws really mean for what we have established.

Any t trade guesses for today?

Lol

http://wallstreetanalyzer.com/2018/05/11/evio-inc-otcqb-evio-ceo-interview/

I’m not best at describing but they are shares hitting the market from purchase deals. Example: the seller of a lab receives new issued shares for their lab instead of cash. Usually they have to be held for a specific amount of time. This last deal was estimated at about 1,000,000 shares so we count the shares logged after hours to predict when this seller is done as this keeps the price down with a constant seller. Most try to buy stock as the dilution is almost done because the stock will no longer be held down. You can tell a t trade because they are four decimal points on the cents which is because the broker who sells these shares for the investor gets a percentage cut from the trading price. That’s the gist of it. There are a few others on this board who would do a better job explaining with proper terminology.

What do we expect for this Q revenues?

What was the fiscal year revenue estimates?

Guess at Q4 revenues?

Still know this fall will be the start of the revenues we’ve been waiting for. Looking forward to when Q1 is released mid Feb.

Where’s Tar been?

That’s 61,800 in t trades. That’s good movement for the day considering that.

Interested to see how many t trades today.

CGC has lowest market cap of the three.

Did you see if there were testing requirements yet?

Which one do you want down? I can replace mine with all the links if you want.

6,000 1.0835

That 23000 1.14 ask isn’t exactly inviting. I have bids at 1.06.

20,000 at about $1.07

News coming? Or is the anticipation of July mandating testing getting around.

The huge resistance block at 1.12 became a huge support block at 1.11